What is the diagnosis and recommended next steps for a 55-year-old postmenopausal woman, 10 weeks after adrenalectomy for an atypical lipid‑poor adrenal tumor, who has markedly elevated total testosterone (~333 ng/dL) and free testosterone (~2.7 ng/dL)?

Diagnosis: Persistent Hyperandrogenism Post-Adrenalectomy – Likely Residual or Metastatic Androgen-Secreting Tumor

This 55-year-old postmenopausal woman with markedly elevated testosterone (333 ng/dL, >10× normal) and free testosterone (2.7 ng/dL) 10 weeks after adrenalectomy for an atypical lipid-poor adrenal tumor most likely has either residual androgen-secreting adrenal tissue, metastatic disease, or a concurrent ovarian androgen-secreting tumor that requires immediate comprehensive imaging and potential surgical intervention.

Critical Context

The combination of an atypical lipid-poor adrenal tumor with Cushing's syndrome and hyperaldosteronism (dual hormone secretion) raises significant concern for adrenocortical carcinoma (ACC), as malignancy should be suspected when tumors are lipid-poor, do not wash out on contrast CT, or secrete more than one hormone 1. The persistently elevated testosterone 10 weeks post-surgery is highly abnormal and demands urgent evaluation.

Immediate Diagnostic Steps

1. Measure DHEAS Immediately

• If DHEAS >600 µg/dL (16,000 nmol/L): This indicates adrenal cortical origin and suggests either incomplete resection, metastatic ACC, or contralateral adrenal pathology 2
• If DHEAS is normal or low: This paradoxically suggests an ovarian source despite the adrenal surgery 2

The testosterone level of 333 ng/dL is well above the tumor threshold (>200 ng/dL or 7 nmol/L) that strongly suggests an androgen-secreting neoplasm 3. However, 25.9% of benign androgen-producing adrenal tumors do not exceed traditional thresholds, so clinical context is paramount 4.

2. Comprehensive Imaging Protocol

Immediately obtain:

• Contrast-enhanced CT chest/abdomen/pelvis to evaluate for:

  • Metastatic disease from potential ACC 1
  • Residual adrenal tissue or contralateral adrenal pathology
  • Retroperitoneal lymphadenopathy

• Pelvic MRI (NOT ultrasound): Transvaginal ultrasound has poor sensitivity for small ovarian tumors, particularly in postmenopausal women with bowel gas interference 5, 6. MRI is superior for detecting small androgen-secreting ovarian tumors (Leydig cell tumors, thecomas, granulosa cell tumors) that can be as small as 2-3 cm 5, 7

3. Additional Hormonal Assessment

Measure the following to localize the source:

• LH and FSH: Suppressed levels suggest autonomous androgen production from tumor 5
• AMH (anti-Müllerian hormone): Low levels (<0.01 ng/mL) in postmenopausal women with elevated testosterone suggest ovarian stromal tumor 5
• Δ4-androstenedione: May be elevated with ovarian sources 2
• Morning cortisol and ACTH: To assess for residual cortisol excess or adrenal insufficiency requiring replacement 1, 8

Critical Diagnostic Pitfalls

The Adrenal Incidentaloma Trap

Multiple case reports demonstrate that concurrent adrenal findings can mislead clinicians away from ovarian pathology 5, 6, 7. In one case, a woman with an adrenal nodule and markedly elevated testosterone ultimately had a Leydig cell tumor of the ovary discovered only after repeat imaging with Doppler ultrasound 7. Another case showed a 2.6 cm ovarian granulosa cell tumor missed on initial ultrasound but detected on MRI 5.

Dexamethasone Suppression Testing

If imaging is initially negative, consider low-dose dexamethasone suppression test (1 mg overnight):

• Paradoxical rise in androgens occurs in ~30% of adrenal androgen-secreting tumors 4
• Suppression suggests ovarian source (though not definitive) 7
• Lack of suppression with adrenal imaging suggests adrenal source

Surgical Decision Algorithm

If Imaging Reveals:

A. Metastatic or Residual Adrenal Disease:

• Open surgical resection (not laparoscopic) for suspected ACC with complete en bloc resection 1
• Consider adjuvant mitotane therapy given high recurrence risk with ACC 9
• Perioperative stress-dose hydrocortisone (150 mg/day) mandatory 1, 9

B. Ovarian Mass (even if small):

• Bilateral salpingo-oophorectomy in postmenopausal women (unilateral surgery risks missing bilateral pathology as seen in 18% of cases) 10, 6, 4
• Laparoscopic approach acceptable for presumed benign ovarian tumors
• Demand permanent pathology – frozen sections miss 100% of granulosa cell tumors in one case series 5

C. No Identifiable Mass on Comprehensive Imaging:

• Consider gonadotropin suppression trial with GnRH agonist (nafarelin 200 µg intranasally daily × 6 weeks) 10
  • Dramatic testosterone decrease suggests occult gonadotropin-responsive ovarian tissue
  • If suppression occurs, proceed to bilateral oophorectomy despite negative imaging
• Alternatively, proceed directly to diagnostic bilateral oophorectomy given the high tumor probability with testosterone >300 ng/dL

Expected Post-Surgical Outcomes

• Testosterone normalization within 3 days to 3 months 10, 5, 11
• Hirsutism/acne improvement within weeks to months 5, 11
• Voice deepening is typically irreversible 5
• Clitoromegaly may partially regress 7

Long-Term Surveillance

Given the atypical nature of the original adrenal tumor and dual hormone secretion:

• Repeat imaging every 3-6 months for 2 years, then annually for 5 years 8
• Annual hormonal evaluation for 5 years (testosterone, DHEAS, cortisol) 8
• Lifelong surveillance for ACC given 10-15% recurrence risk and potential for late metastases 9

Bottom Line

Do not assume the adrenalectomy resolved the hyperandrogenism. The persistently elevated testosterone 10 weeks post-surgery is pathologic and requires aggressive investigation for either malignant adrenal disease or concurrent ovarian pathology. Pelvic MRI and DHEAS measurement are the immediate next steps, followed by surgical exploration if any mass is identified or if no mass is found despite tumor-range testosterone levels 5, 6, 7, 4.